Hypertension is strongly associated with coronary heart disease, where a 10-mm Hg change in blood pressure (BP) reduces the risk of this condition by 37%. 1 It is imperative to effectively control BP levels to reduce the risk of cardiovascular events. 2 However, in a cross-sectional analysis of the Framingham Heart Study, only 48% of treated hypertensive patients and <40% of elderly participants were controlled to <140/90 mm Hg. 3 A significant number of these uncontrolled patients were classified as having resistant hypertension (RHTN)-defined as high BP levels despite the use of at least 3 antihypertensive agents or controlled BP with at least 4 antihypertensive drugs. 4 Resistant hypertensive patients have a higher incidence of target organ damages (TOD) and its markers such as endothelial dysfunction, microalbuminuria, and left ventricular hypertrophy (LVH). 5,6 TOD poses greater incidence of cardiovascular events, such as myocardial infarction, 7 that might be due to (i) aging and diabetes 5 and (ii) more atherosclerotic plaques. 8 Thus, clinicians must be aware of the potential for silent ischemia and the need for early diagnostic tests for myocardial ischemia. Myocardial perfusion scintigraphy with (99m)tc-sestamibi can accurately diagnose coronary artery disease in asymptomatic patients with hypertension. 9,10 However, appropriate consideration of predictors of myocardial ischemia in this subpopulation of hypertensive subjects may help to avoid extra costs in detecting myocardial ischemia.
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We investigated myocardial ischemia in resistant hypertensive subjects and compared clinical and laboratory characteristics of patients with and without scintigraphy abnormalities to define predictors of myocardial ischemic alterations in these subjects.
METHODS
This study was approved by the Research Ethics Committee of the Faculty of Medical Sciences, University of Campinas (Campinas, Brazil), and each participant provided signed written consent. This study was carried out according to the Declaration of Helsinki.
Study population
In this cross-sectional study, 129 consecutive subjects classified as resistant hypertensive patients according to international guidelines 4 were enrolled from the Resistant Hypertension Clinic at University of Campinas (Campinas, Brazil). All patients underwent myocardial perfusion scintigraphy with pharmacological stress for evaluation of myocardial ischemia between 2008 and 2012. According to the scintigraphy findings, they were divided into 2 groups: (i) patients with myocardial ischemia (I-RHTN; n = 36) and (ii) patients without myocardial ischemia (NI-RHTN; n = 93). The diagnosis of RHTN-defined as uncontrolled BP with the use of 3 antihypertensive drugs or controlled BP with the need for at least 4 drugs-was given after at least 6 months of follow-up, confirmation of the need for the prescribed medications, and certification of the BP levels with correctly measured office BP levels and through ambulatory BP monitoring (ABPM) to exclude white coat hypertension. 4, 11 Pseudoresistance due to medication nonadherence and to secondary causes of hypertension were excluded. 12, 13 Adherence was evaluated by pill count method and using the Morisky questionnaire. 14 Nonadherent subjects (with adherence rate <80% of the prescribed medication) were excluded. All BP measurements were performed according to the current guidelines. 4, 11 Patients with obstructive sleep apnea previously diagnosed by polysomnography or with moderate to high risk of obstructive sleep apnea by the Berlin sleep questionnaire were also excluded. 15 Subjects with prior coronary events or who were symptomatic for coronary obstructions, such as exertional angina, were also excluded.
Myocardial perfusion scintigraphy
A dual-headed camera (Millenium MG; GE Medical Systems, Milwaukee, WI) with a high-resolution collimator rotated in a 180° orbit and able to acquire 64 projections (20 seconds per projection) was used in this study. The images were obtained after 45 minutes of (99m)tc-sestamibi infusion (925-1,480 MBq) at rest and after vasodilator stress induced by dipyridamole. Images were interpreted by 2 experienced observers, independently, and the interobserver variability was 5%. Semiquantitative visual interpretation of myocardial perfusion was performed with short-axis and vertical long-axis tomograms, 16 and correction for attenuation was performed. The myocardial perfusion defects were described regarding the extent of the lesions and the presence of the reversibility areas, intensity of the defect, and location. Quantitative analysis was performed after an evaluation of a 17-myocardial segment approach. Each segment is graded through a 5-point scoring system. 16 Images were compared at rest and after pharmacological stress. Scarring in the myocardium was considered present if the perfusion defects were irreversible and ischemic when they were reversible. According to these parameters, results were given as definitive or transient hypoperfusion areas, with the transient corresponding to myocardial ischemia. 16 Patients with values >6% of transient hypoperfusion were considered as having a positive exam for myocardial ischemia.
BP measurements
Office BP measurements were recorded 3 times using a digital sphygmomanometer (Omron HEM-711DLX; OMRON Healthcare, Bannockburn, IL) on the right upper arm in the sitting position after a 10-minute rest. The average of 2 consecutive measurements was used when a variation <5 mm Hg was encountered. 17 Twenty-four-hour ABPM was carried out with an automatic device (Spacelabs 90217; SpacelabsInc, Redmond, WA). 18 Patients were oriented to keep normal daily activities, and BP was measured at 20-minute intervals during a 24-hour period. The parameters measured were average 24-hour systolic BP, diastolic BP, mean BP, pulse pressure, and dipper status.
Endothelial function assessment
Brachial artery dilation was measured by linear vascular transducer (4-13 MHz, Siemens Acuson CV70; Siemens, Munich, Germany). The brachial artery flow-mediated dilation test was performed according to current guidelines. 19, 20 All studies were initiated at 8:00 am after overnight fasting with the subjects in a supine position in a quiet, air-conditioned room (22-24 °C) . Diameter of the brachial artery was taken 5 cm above the elbow. A polyurethane cuff (Hokanson, Bellevue, WA) was placed on the forearm and inflated for 5 minutes at a 250-mm Hg pressure and quickly deflated. After 45 seconds a new diameter was recorded at the exact site of the prior assessment. Changes in the brachial artery diameter were expressed as a percentage relative to the vessel diameter before cuff inflation. The vascular function examination was performed by 2 experienced blinded examiners, and there was no significant interobserver (5%) or intraobserver (2.5%) measurement variability. No subject had baseline brachial diameter >6.0 mm.
Echocardiography
The measurements of the dimensions of the left ventricle were performed according to the American Society of Echocardiography recommendations using 2-dimensional targeted M-mode echocardiography. Left ventricular (LV) diastolic diameter (LVDD) and LV systolic diameter (LVSD), as well as the interventricular septal (IVS) thickness and LV posterior wall thickness at the end of diastole, were measured according to the QRS wave of electrocardiography. Ejection fraction was calculated by the Teicholz method, LV mass was inferred with the specific formula published elsewhere, 21 and LV mass index (LVMI) was calculated by dividing LV mass by the body surface. Doppler parameters were early mitral inflow peak (E-wave) and late diastolic peak (A-wave) velocities, in order to calculate E/A ratio. 22 Echocardiographic measurements were evaluated by 2 blinded independent investigators using cardiovascular ultrasound machine (Siemens Acuson CV70; Siemens) with multifrequency sector transducer (2-4 MHz). The intraobserver and interobserver coefficients of variation of the LVDD, LVSD, interventricular septal thickness, and LV posterior wall thickness were <5.5% and 9.5% for LVMI.
Statistical analysis
Categorical variables were expressed as percentages (%), and continuous data were expressed as mean and SD when normally distributed or as median and interquartile range when the distribution was non-normal. Continuous variables were compared using Student t tests or Mann-Whitney tests according to distributions. Categorical variables were compared using χ 2 or Fisher exact tests. A multiple logistic regression model including the variables age, diabetes, body mass index, heart rate (HR), LVMI, and microalbuminuria for the presence of myocardial ischemia was performed. The level of significance (α) accepted was 0.05 (two-sided P value). The analyses were performed using SigmaPlot software (version 12; Systat Software, Chicago, IL).
RESULTS
The demographic and clinical characteristics of study population are shown in Table 1 . The proportion of patients with uncontrolled BP was not different between I-RHTN and NI-RHTN (53% vs. 66%). Overall, the mean age of patients with RHTN was 54 ± 11 years; 39 (30%) were men. No statistical differences were observed between I-RHTN and NI-RHTN in regards to age and sex. Body mass index and diabetes frequency were higher in I-RHTN patients. Laboratory parameters were similar in both groups, except for microalbuminuria, which was higher in the I-RHTN group (Table 1 ). The extent of ventricular mass with reversible perfusion defects (ischemia) was 9% ± 3% among patients in the I-RHTN group according to scintigraphy findings.
Office BP and ABPM measurements were similar in both I-RHTN and NI-RHTN patients. Flow-mediated dilation was significantly lower in the I-RHTN group (Table 2) . There was no difference in 24-hour ABPM dipper patterns between the 2 groups.
Echocardiography evaluation revealed no difference in ejection fraction between the groups. However, left atrial diameter, septal wall thickness, posterior wall thickness, LVDD, LV mass, LVMI, and E/A ratio were higher in the I-RHTN group when compared with the NI-RHTN group. The predominant pattern of LV hypertrophy was concentric (Table 3) .
Multivariable logistic regression analysis adjusted for body mass index and age showed that diabetes (OR = 6.5; 95% CI = 1.06-40.14; P = 0.04), flow-mediated dilation (OR = 0.18; 95% CI = 0.07-0.41; P < 0.001), HR (OR = 1.23; 95% CI = 1.11-1.36; P < 0.001), LVMI (OR = 1.02; 95% CI = 1.01-1.04; P = 0.04), and microalbuminuria (OR = 1.02; 95% CI = 1.01-1.04; P = 0.002) were independent predictors of ischemia (Table 4) . Similar results were obtained when adjusting for age and sex, with the same independent variables above. No interactions were found between all independent variables in the regression.
DISCUSSION
We assessed the presence of the myocardial perfusion abnormalities detected by scintigraphy in a population of asymptomatic RHTN patients. Our main findings were an association of the presence of myocardial ischemia with diabetes, endothelial dysfunction, HR, microalbuminuria, and LVMI. Hence, myocardial ischemia was predicted by microalbuminuria, LVMI, HR, presence of diabetes, and flow-mediated dilation.
Ischemic patients had more diabetes, in agreement with other observational studies in which diabetes is not only more prevalent in coronary disease patients but is also considered an important risk factor. 23 We found a prevalence of 28% of silent myocardial ischemia in patients with RHTN. Previous studies showed that 14% of nondiabetic patients, 26% of diabetic patients, 24 and 28% of diabetic patients with known coronary artery disease (CAD) have myocardial ischemia. Also, the presence of hypertension combined with diabetes impact more myocardial ischemia than hypertension in nondiabetic patients (29% vs. 12%). 25 The high prevalence of myocardial ischemia in our asymptomatic sample shows the importance of RHTN as a risk for myocardial ischemia, comparable with the risk of diabetic patients with already diagnosed CAD.
Flow-mediated dilation, a reflection of endothelial function, was more impaired in the group of I-RHTN subjects. Endothelial dysfunction is associated with increased cardiovascular events and atherosclerosis risk factors, especially in hypertensive patients, 26 and it has been considered a predictor of coronary disease in individuals with stable angina. 27 Because flow-mediated dilation was not affected by differences in drug therapy in our sample, our findings suggest that endothelial dysfunction may be closely related to myocardial ischemia in RHTN.
There is a high prevalence of TOD in resistant hypertensive subjects. 28 The presence of TOD due to hypertension is more common and is even a predictor of vascular events and mortality in subjects with vascular disease. 29 In our specific set of patients (RHTN), who are per se more afflicted by TOD, 5 we observed a similar finding-that is, RHTN patients with myocardial ischemia presented with greater microalbuminuria and increased LV mass. Microalbuminuria, also found to be an independent predictor of myocardial ischemia in our sample, has previously been shown to be strongly associated with cardiovascular morbidity in RHTN, especially with coronary heart disease. 30 These links between altered renal protein excretion and cardiovascular morbidity can likely be explained by widespread arterial damage, endothelial dysfunction (also a predictor of ischemia in our sample), and systemic inflammation. 31 Elevated resting HR is long known to be a risk factor for coronary artery disease. 32 We found that HR, measured by 24-hour ABPM, was higher in the patients presenting with myocardial ischemia than in those with normal myocardial perfusion. In fact, HR is increased in RHTN individuals with uncontrolled BP compared with control groups. 33 Thus, in our sample, the higher HR in the I-RHTN group could be explained by increased sympathetic activity reflecting autonomic imbalance in this subpopulation of hypertensive subjects, as previously described by our group, especially when associated with diabetes. 34 PRA, ng/mL per h, mean ± SD 1.88 ± 0.61 2.32 ± 0.73 ARR, ng/dl per ng/ml per h, mean ± SD 12.9 ± 8.5 10.3 ± 2.7
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARA II, angiotensin II receptor blockers; ARR, aldosterone-renin ratio; BMI, body mass index; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MA, microalbuminuria; PAC, plasma aldosterone concentration; PRA, plasma renin activity; RHTN, resistant hypertension; UK, urinary potassium concentration; UNa, urinary sodium concentration. *P < 0.05 vs. NI-RHTN; **P < 0.001 vs. NI-RHTN.
TOD increases along with BP levels. 28 Interestingly, in our study, in the I-RHTN group, the association between BP levels and TOD was not maintained, with the prevalence of TOD being higher, with no increment on the levels of BP, compared to NI-RHTN. Explanations of this discrepancy between higher TODs without BP increases in the I-RHTN group have yet to emerge but may be related to the fact that both LVH and decreased BP may worsen myocardial ischemia by reducing perfusion pressure, as demonstrated by Mansour et al. 35 In regards to the echocardiographic parameters, we also encountered significant differences in left atrial diameters and E/A ratio between groups. Although diastolic dysfunction was not completely assessed, the increase in left atrium dimensions and the lower ratio between Doppler waves E and A suggest more impaired diastolic function in the I-RHTN group. 36 Myocardial perfusion scintigraphy was used in this study because it is a noninvasive method and provides incremental prognostic information beyond clinical and exercise electrocardiogram data. 37 Myocardial perfusion scintigraphy has the ability to detect not only epicardial obstructions but also microvascular alterations in hypertensive patients, in Table 3 . Echocardiographic variables in patients with and without myocardial ischemia Eccentric hypertrophy 9 (25) 25 (27) Abbreviations: E/A, early diastolic filling velocity/atrial diastolic velocity; I-RHTN, resistant hypertension with myocardial ischemia; LV, left ventricular; NI-RHTN, resistant hypertension without myocardial ischemia; RHTN, resistant hypertension. Data are presented as mean ± SD or median (1st-3rd quartiles). *P < 0.05 vs. NI-RHTN; **P < 0.001 vs. NI-RHTN. Flow-mediated dilation, % 6.9 (5.8-7.2)** 7.9 (7.0-8.8)
Abbreviations: ABPM, 24-hour ambulatory blood pressure monitoring; DBP, diastolic blood pressure; HR, heart rate; I-RHTN, resistant hypertension with myocardial ischemia; NI-RHTN, resistant hypertension without myocardial ischemia; PP, pulse pressure; RHTN, resistant hypertension; SBP, systolic blood pressure. Data are presented as mean ± SD or median (1st-3rd quartiles). **P < 0.001 vs. NI-RHTN.
contrast to stress echocardiography, which has a poor ability to identify abnormalities of the microvascular coronaries. 38 The use of dipyridamole as a stress inducer is comparable with exercise. 39 Stress myocardial perfusion scintigraphy has high sensitivity (81%-96%), specificity (67%-89%), and diagnostic accuracy (83%-92%) for detecting CAD. 40 Evaluation of the accuracy of noninvasive imaging techniques for diagnosis of CAD is relevant for the appropriate management of patients with hypertension, one of the most common cardiac risk factors. 41 To the best of our knowledge this is the first study to evaluate myocardial ischemia in resistant hypertensive patients, leading to the determination of variables associated with these myocardial perfusion abnormalities. Two previous studies have assessed silent myocardial ischemia by electrocardiogram monitoring, but not with a precise diagnose of RHTN, 42 or the study was done in essential hypertensive subjects. 43 The main limitation of our study is that the ischemia was not investigated by coronary angiogram, which would have allowed detection of disease of the epicardial coronaries. However, this investigation was not performed for ethical issues because the majority of ischemic patients had no symptoms and small areas of ischemia, making clinical treatment the best option. 44 Another limitation might be the false-negative results provided by myocardial perfusion imaging in cases of balanced myocardial ischemia, in which the diseases on coronary arteries are distributed throughout the coronary circulation, complicating interpretation of differences in perfusion between the myocardial segments in stress and at rest. 45 As to adherence assessment, the methods used (Morisky and pill count) are indirect and may not entirely exclude nonadherent subjects. Regarding our sample, the limitation might be that it is a single-center study with a convenience sample.
Taken together, our data indicate that clinicians should be aware of predictors of silent myocardial ischemia in RHTN. Regardless of BP levels, our findings suggest that microalbuminuria, LV mass, endothelial function, presence of diabetes and increased HR play a relevant role when assessing coronariopathy and myocardial ischemia in patients with truly RHTN. The presence of these factors suggests that special attention on silent myocardial ischemia should be given to patients with RHTN. As a perspective, we feel that because the patients are asymptomatic, but carry a high risk for presenting myocardial ischemia, an individualized investigation should be performed. With the presence of these identifiable associated factors, myocardial perfusion scintigraphy would be of significant importance in screening these RHTN patients for myocardial ischemia.
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